---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010393"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T20:15:16.826055+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture

## Summary
- GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
- Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.
- Protein Sciences segment organic growth 4% (reported 6%) in Q4.
- Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.
- Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18.

## SEC filing metadata
- accession: 0001558370-25-010393
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/0001558370-25-010393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/tech-20250806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010393
- JSON: https://secwatch.observer/filing/0001558370-25-010393.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.